pharma · Multiple Myeloma · Relapsed/Refractory Multiple Myeloma
Janssen-Cilag International N.V
Janssen-Cilag International N.V.
Janssen-Cilag Farmaceutica Ltda is a pharma organization headquartered in São Paulo, EU. Primary therapeutic focus areas include Multiple Myeloma, Relapsed/Refractory Multiple Myeloma, Inflammatory Conditions, Moderately
São Paulo, EU HQ
13 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- São Paulo, EU
- Employees
- 13
- Programs
- 161
- Drugs
- 159
- Patents
- 0
42756493BLC3004
Phase 3 · small molecule · FGFR+ Intermediate-risk Non-muscle Invasive Bladder Cancer
42756493BLC3004 for FGFR+ Intermediate-risk Non-muscle Invasive Bladder Cancer is a Phase 3 program (small_molecule) at Janssen-Cilag International N.V. with 1 ClinicalTrials.gov record(s).
Internal code 42756493BLC3004
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Janssen-Cilag International N.V.
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- FGFR+ Intermediate-risk Non-muscle Invasive Bladder Cancer
- Status
- active
- Trials
- 1